Completed PHASE4 INTERVENTIONAL 2-arm NCT03014700

Fibrinogen Concentrate vs Cryoprecipitate

Repurposing of Fibrinogen Concentrate as a Cost-Effective and Safe Hemostatic Agent in Infants Undergoing Cardiac Surgery on Cardiopulmonary Bypass

Sponsor: Emory University

Conditions Congenital Heart Disease

Interventions Cryoprecipitate Fibrinogen Concentrate

Updated 10 times since 2017 Last updated: Apr 14, 2019 Started: Mar 31, 2016 Primary completion: Apr 25, 2018 Completion: Apr 25, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Congenital Heart Disease and is currently completed. Emory University leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 5 earlier versions

Jun 2019 — Jan 2021 [monthly]

Completed PHASE4
Oct 2018 — Jun 2019 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jun 2018 — Oct 2018 [monthly]

Recruiting PHASE4
Jun 2017 — Jun 2018 [monthly]

Recruiting PHASE4
Feb 2017 — Jun 2017 [monthly]

Recruiting PHASE4

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Emory University
Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Emory, United States
• Stanford, United States